Even in Denmark — Novo Nordisk's household market place — an software for Wegovy to obtain community well being insurance policies coverage was turned down over the grounds that its cost was incommensurate with its therapeutic worth.Meantime, source constraints could dampen initial distribution in the current market forecast to become worth $20